Functional Neurological Disorder (FND) is characterized by neurological symptoms that are inconsistent with recognized structural disease yet are experienced as very real and often disabling. Core clinical features commonly include weakness or paralysis that does not follow typical anatomical patterns, tremor or jerks that can vary with distraction, episodes resembling epileptic seizures without the electrical changes seen in epilepsy (often called functional seizures or dissociative seizures), and sensory disturbances such as numbness, tingling, or visual loss. Symptoms may fluctuate markedly over short periods of time, and clinicians frequently note internal inconsistency on examination, such as a limb appearing weak during one test but functioning normally during another task. Many people with FND report accompanying problems with balance, gait disturbance, dizziness, and “brain fog,” along with heightened anxiety, sleep disturbance, and autonomic symptoms such as palpitations or gastrointestinal upset.
Fibromyalgia is a chronic pain condition defined by widespread musculoskeletal pain and tenderness, typically affecting both sides of the body and present for at least three months. The pain is often described as aching, burning, or throbbing, and may shift in intensity and location over time. A striking feature is the combination of pain and fatigue; people frequently describe feeling unrefreshed after sleep, exhausted by minimal exertion, and limited in daily activities. Cognitive difficulties, often called “fibro fog,” include problems with concentration, word-finding, and memory. Additional common manifestations include sleep disturbances, headaches or migraines, heightened sensitivity to touch, light, and sound, and mood symptoms such as anxiety and depression. Many patients also report comorbid symptoms from other organ systems, including irritable bowel–type gastrointestinal complaints, urinary urgency, and pelvic pain, reinforcing the idea of a systemic dysregulation rather than a localized musculoskeletal problem.
Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder defined by recurrent abdominal pain associated with a change in bowel habits in the absence of structural or biochemical abnormalities. The abdominal pain may be crampy, sharp, or diffuse, often related to defecation, and can be accompanied by bloating, a sense of abdominal distension, and excessive gas. Patterns of bowel disturbance vary between individuals and over time, with subtypes including IBS with constipation, IBS with diarrhea, and mixed or alternating forms. Patients frequently report urgency, a sensation of incomplete evacuation, and symptom flares triggered by certain foods, hormonal changes, or stress. Extraintestinal symptoms are also common, such as nausea, early satiety, back pain, pelvic discomfort, and disturbed sleep, and they frequently coexist with anxiety and depressive symptoms.
One of the striking clinical observations across FND, fibromyalgia, and IBS is the degree of overlap in symptom profiles despite their different primary organ systems. Pain and fatigue are central complaints in fibromyalgia but are also highly prevalent in FND, where musculoskeletal discomfort, headaches, and generalized tiredness often coexist with functional weakness or seizures. IBS is anchored in abdominal pain, yet many individuals also experience generalized body pain, joint or muscle aches, and profound fatigue that impair work, social functioning, and physical activity. Cognitive complaints, including concentration and memory problems, appear in all three conditions and are often exacerbated by poor sleep and psychological distress.
Another shared clinical characteristic is the prominence of sensory amplification and intolerance to normal bodily sensations. People with fibromyalgia frequently describe even light touch or mild pressure as painful, consistent with heightened pain processing. Individuals with FND may perceive normal bodily sensations, such as minor twitches or transient dizziness, as alarming, contributing to escalating symptoms and functional impairment. IBS patients often become acutely aware of normal gas movement or intestinal contractions, experiencing them as painful or distressing, with bloating and discomfort that seem disproportionate to objective abdominal findings. This pattern of amplified perception is consistent with central sensitization, a phenomenon in which the central nervous system becomes hyper-responsive to sensory inputs.
Stress responsivity and emotional factors also show similar clinical patterns across these conditions. In FND, symptom onset or exacerbation often follows periods of acute stress, interpersonal conflict, medical illness, or physical injury. Fibromyalgia frequently emerges after a triggering event, such as infection, trauma, surgery, or major life stress, with subsequent flares linked to emotional strain, sleep loss, or overexertion. In IBS, many people notice that emotional stress, anxiety, and situational pressures aggravate abdominal pain, urgency, or bowel habit changes, even when diet remains stable. Patients across all three conditions often report a heightened startle response, difficulty relaxing, and a sense of being “on edge,” even when they do not meet full criteria for a psychiatric disorder.
Autonomic and somatic symptoms cluster in ways that further blur traditional diagnostic boundaries. People with FND may report palpitations, shortness of breath, sweating, and temperature dysregulation, alongside dizziness on standing and “blackout” episodes. Fibromyalgia commonly includes orthostatic intolerance, cold extremities, frequent headaches, temporomandibular joint pain, and sensitivities to noise and light. IBS patients often describe overlapping bladder symptoms, menstrual pain, sexual discomfort, and non-cardiac chest pain. Taken together, these multi-system complaints contribute to complex clinical pictures that defy a single-organ explanation and require clinicians to consider patterns of overlap rather than viewing each syndrome in isolation.
The chronic and fluctuating nature of these conditions also shapes their clinical course. Symptoms in FND may wax and wane dramatically, with some individuals experiencing complete remission of certain manifestations while others develop new symptom types over time, such as evolving from transient weakness to functional seizures. Fibromyalgia symptoms often follow a relapsing-remitting pattern influenced by sleep quality, activity levels, and stress exposure, with periods of relative control interspersed with debilitating flares. IBS likewise tends to be chronic but variable, with symptom-free intervals in some people and more persistent, daily discomfort in others. Across all three conditions, symptom unpredictability can be as disabling as the symptoms themselves, eroding confidence, limiting planning, and contributing to social withdrawal.
The lived experience of FND, fibromyalgia, and IBS shares recurring themes that are clinically important: feelings of not being believed, frustration with inconclusive tests, and difficulty navigating healthcare systems that are often organized around single specialties. Many individuals have seen multiple providers before receiving a clear explanation for their symptoms, and they may carry overlapping labels such as chronic fatigue, migraine, pelvic pain, or anxiety disorders alongside their primary diagnosis. These shared clinical characteristics underscore that while FND, fibromyalgia, and IBS are defined by different symptom clusters, they often coexist in the same person and interact in complex ways, setting the stage for high symptom burden and significant functional impairment.
Shared pathophysiology and mechanisms of symptom overlap
Understanding why FND, fibromyalgia, and IBS so often occur together requires looking beyond individual organs and focusing on how the brain, spinal cord, and body communicate. A central concept is disordered processing of sensory information in the nervous system, sometimes referred to as central sensitization. In this state, neural networks involved in detecting and interpreting sensations become overly responsive, so that normal or mildly noxious inputs are experienced as disproportionately intense, unpleasant, or threatening. This helps explain why people with fibromyalgia feel widespread musculoskeletal pain without evidence of joint or tissue damage, why those with IBS experience severe abdominal pain and bloating despite normal endoscopy or imaging, and why individuals with FND can have dramatic neurological symptoms in the absence of structural brain lesions. These phenomena are not imagined; they reflect real changes in how the nervous system amplifies and prioritizes certain bodily signals.
In all three conditions, functional brain imaging studies have demonstrated altered activity in regions involved in sensory processing, affect regulation, and interoception—the brain’s perception of internal bodily states. Areas such as the insula, anterior cingulate cortex, prefrontal cortex, and somatosensory cortices often show atypical activation patterns in response to pain or other bodily stimuli. In fibromyalgia, for example, stimuli that are ordinarily perceived as mildly uncomfortable can trigger exaggerated responses in pain-processing networks, consistent with central sensitization. In IBS, the gut’s normal motility or distension can be registered in the brain as disproportionately painful or urgent. In FND, areas involved in voluntary movement, attention, and self-awareness may become functionally “uncoupled,” so that movements feel involuntary or entirely blocked, even though basic motor pathways remain intact. These overlapping brain circuitry changes support the idea of a shared neurobiological vulnerability that can manifest as different symptom constellations depending on context and individual factors.
Another unifying mechanism involves dysregulation of the autonomic nervous system, which controls heart rate, blood pressure, gut motility, sweating, and other automatic functions. Many people with FND, fibromyalgia, and IBS show evidence of heightened sympathetic activity—the “fight or flight” branch—and reduced parasympathetic tone, which ordinarily supports rest, digestion, and recovery. Clinically, this can present as palpitations, dizziness on standing, sweating, temperature sensitivity, and variable bowel habits, often in the absence of primary cardiovascular or endocrine disease. Autonomic dysregulation contributes to sleep disturbance, non-restorative rest, and daylong tiredness, helping to link pain and fatigue into a self-perpetuating cycle. It can also amplify gut sensitivity and motility changes in IBS and exacerbate dizziness, faintness, and other somatic experiences that feed into FND symptoms.
The body’s main stress-response system, the hypothalamic-pituitary-adrenal (HPA) axis, also appears to be altered across these conditions. Research has identified patterns such as blunted or delayed cortisol responses to stress, flattened daily cortisol rhythms, and increased inflammatory signaling in some individuals with fibromyalgia, IBS, and FND. Rather than a single consistent abnormality, the common theme is a stress system that has lost flexibility, becoming either over-reactive or under-responsive to everyday challenges. Repeated or chronic stress may sensitize neural circuits that process threat and pain, leading to heightened vigilance toward bodily sensations and difficulty returning to baseline after stressors pass. Over time, this can reinforce central sensitization, contribute to persistent pain and fatigue, and maintain autonomic instability.
Interoception—the brain’s monitoring and interpretation of signals from the heart, lungs, gut, muscles, and other organs—plays a crucial role in symptom overlap. In healthy states, interoceptive signals guide adaptive behaviors, such as resting when tired or seeking food when hungry. In FND, fibromyalgia, and IBS, interoceptive processing can become distorted, leading to either hyper-awareness of minor fluctuations or difficulty accurately interpreting signals. For instance, normal gut contractions might be perceived as painful cramps in IBS, minor muscle tension might be experienced as severe pain in fibromyalgia, and transient dizziness or tingling might be interpreted as a sign of impending collapse or paralysis in FND. These misinterpretations are often not conscious choices; they arise from altered predictive processing, in which the brain’s expectations and prior experiences shape how incoming signals are perceived.
Predictive processing frameworks suggest that the brain constantly generates predictions about bodily states and then updates them based on sensory input. When prediction and input do not match, prediction errors are used to refine internal models. In FND, fibromyalgia, and IBS, prior experiences of illness, pain, or threat, combined with heightened attention to bodily sensations, may bias predictions toward danger or dysfunction. If the brain strongly “expects” pain, weakness, or gut disturbance, even relatively normal signals can be interpreted in line with those expectations. This does not mean symptoms are voluntary or under conscious control; rather, it highlights how learning, attention, and emotion can shape symptom generation. Over time, maladaptive predictions can become entrenched, strengthening neural pathways that sustain overlapping symptoms across conditions.
Inflammation and immune signaling represent another area of partial convergence. While classic markers of systemic inflammation are often normal in these conditions, subtler alterations in cytokines and immune-cell function have been observed. Low-grade immune activation can modulate neural circuits involved in mood, energy, and pain sensitivity, helping to explain why pain, fatigue, and cognitive fog cluster together. In some individuals, infections, surgery, or other inflammatory events precede the onset of fibromyalgia, IBS, or FND-like symptoms, suggesting that immune challenges can act as triggers in a vulnerable nervous system. Microglial activation in the central nervous system, still being actively researched, may be one mechanism by which immune signals contribute to central sensitization and symptom persistence across syndromes.
The gut–brain axis is particularly relevant to the intersection of IBS with FND and fibromyalgia but also offers broader insights into shared mechanisms. The gut microbiome influences immune function, neurotransmitter production, and vagal nerve signaling, all of which affect brain function and pain perception. Dysbiosis—an imbalance in gut microbial communities—has been described in IBS and, to a lesser extent, in fibromyalgia. Changes in microbial metabolites can alter intestinal permeability, promote low-grade inflammation, and sensitize gut sensory pathways, leading to visceral hypersensitivity. Through neural and humoral pathways, these gut-derived signals can reach brain regions implicated in mood regulation and pain processing, potentially contributing to widespread pain and fatigue, as well as to increased bodily vigilance that can feed into FND symptom expression.
Psychological and social factors do not cause these conditions on their own, but they shape how biological vulnerabilities are expressed and maintained. Early life adversity, chronic stress, and certain personality traits—such as high harm avoidance or perfectionism—have been associated with greater risk of developing overlapping syndromes. These experiences can influence HPA axis function, autonomic balance, and the development of neural networks involved in emotion regulation and threat detection. Once symptoms begin, understandable fear, confusion, and negative healthcare experiences can deepen attention to symptoms, reinforce catastrophic interpretations, and reduce engagement in restorative activities. This can entrench patterns of avoidance and deconditioning, thereby intensifying pain and fatigue and increasing the likelihood that multiple diagnostic labels—such as FND, fibromyalgia, and IBS—will accumulate over time in the same person.
Motor control and body schema disturbances are particularly salient in FND but share conceptual links with sensory and interoceptive alterations in fibromyalgia and IBS. Body schema refers to the brain’s internal map of the body in space. Disruptions in this map can lead to sensations of heaviness, disconnection, or altered ownership of limbs in FND, as well as functional weakness or tremor. Interestingly, similar though less dramatic distortions of body perception have been reported in fibromyalgia, such as feeling that a limb is swollen or misshapen when it appears normal. These distortions are thought to arise from imbalances between sensory input, motor output, and top-down predictions. When combined with central sensitization and heightened bodily vigilance, such disturbances may create a fertile ground for multiple symptom domains—neurological, musculoskeletal, and gastrointestinal—to become simultaneously disrupted.
Learning and conditioning processes help explain why symptoms can spread from one system to another and why flare-ups in one domain often coincide with worsening in others. If an individual with IBS repeatedly experiences severe abdominal pain and urgency during stressful situations, the brain may begin to associate certain contexts, emotions, or bodily cues with impending gastrointestinal distress. Over time, similar learning can occur in relation to pain and fatigue in fibromyalgia or functional weakness and seizures in FND. These associative networks can generalize, so that a wide range of triggers—such as poor sleep, minor illness, or interpersonal conflict—can provoke multi-system flares. The overlap in triggers and the shared involvement of stress and arousal circuits help to synchronize symptom patterns, making it common for pain, bowel disturbance, and neurological symptoms to worsen in tandem.
Sex hormones and gender-related factors may further modulate shared mechanisms. FND, fibromyalgia, and IBS are all more commonly diagnosed in women, though they clearly affect people of all genders. Fluctuations in estrogen and progesterone can influence pain sensitivity, gut motility, and emotional processing, potentially contributing to symptom variability across the menstrual cycle or during menopause. Societal and cultural expectations may also shape help-seeking behavior, symptom reporting, and how clinicians interpret complaints, leading to different diagnostic pathways for similar biological phenomena. These gendered patterns do not explain the conditions fully, but they intersect with neurobiological and psychosocial mechanisms to shape the expression and overlap of syndromes across individuals and populations.
Altogether, the convergence of altered central processing, autonomic and HPA axis dysregulation, interoceptive and predictive processing changes, low-grade immune and inflammatory influences, and learned associations provides a coherent framework for understanding why FND, fibromyalgia, and IBS so often coexist. Rather than implying a single cause, this framework emphasizes a network of interacting systems that can become dysregulated in related ways. Depending on genetic predisposition, life experiences, environmental exposures, and chance, these dysregulations can be channeled more toward neurological manifestations, widespread musculoskeletal pain, or gastrointestinal disturbance—yet the underlying vulnerabilities often remain shared, setting the stage for ongoing overlap and complex clinical presentations.
Diagnostic challenges and differential considerations
Diagnostic assessment in the context of overlapping FND, fibromyalgia, and IBS is complicated by the fact that symptoms are often diffuse, fluctuating, and not easily captured by standard tests. Many individuals present with a long list of complaints—widespread pain and fatigue, abdominal discomfort, bowel irregularity, dizziness, functional weakness, or non-epileptic seizure-like events—none of which point clearly to a single, organ-based disease. Traditional biomedical models, which prioritize structural abnormalities and laboratory abnormalities, can struggle to accommodate this pattern. When imaging, blood work, endoscopy, and neurophysiologic investigations return normal or only mildly abnormal results, clinicians may feel uncertain about how to interpret the symptom burden, and patients may experience invalidation or suspicion that their symptoms are “all in their head.” This disconnect between lived experience and objective findings is a core diagnostic challenge.
A crucial but often misunderstood point is that all three conditions are positive diagnoses made on the basis of characteristic clinical features, not diagnoses of exclusion made only after “everything else” has been ruled out. For FND, modern diagnostic criteria emphasize specific signs on neurological examination and video-EEG that demonstrate internal inconsistency and reversibility of symptoms, such as Hoover’s sign for functional leg weakness or distractibility of tremor. Fibromyalgia is defined by chronic widespread pain, symptom severity scores, and associated features like sleep disturbance and cognitive fog, rather than by tender point counting alone or exclusion of every other pain condition. IBS relies on symptom-based criteria such as the Rome guidelines, centering on recurrent abdominal pain associated with changes in stool form or frequency. Recognizing these positive diagnostic frameworks helps prevent endless testing and supports timely identification of comorbid or overlapping syndromes.
At the same time, careful differential diagnosis remains essential to avoid missing treatable structural or inflammatory pathologies that can mimic or coexist with FND, fibromyalgia, or IBS. For neurological presentations, clinicians must distinguish functional seizures from epileptic seizures, functional weakness from stroke or demyelinating disease, and functional movement disorders from degenerative conditions like Parkinson’s disease. Red flags include sudden onset of persistent focal deficits, progressive deterioration, clear structural lesions on MRI, or unequivocal epileptiform activity on EEG that correlates with events. In fibromyalgia-like presentations, systemic inflammatory or autoimmune diseases (such as rheumatoid arthritis, lupus, or polymyalgia rheumatica), endocrine disorders (like hypothyroidism or Cushing’s syndrome), and metabolic abnormalities (for example, vitamin B12 deficiency) should be considered, especially when there are objective joint swelling, marked inflammatory markers, or organ-specific signs.
For IBS, differential considerations include inflammatory bowel disease, celiac disease, colorectal cancer, microscopic colitis, pancreatic insufficiency, and various malabsorption syndromes. Alarm features such as unexplained weight loss, gastrointestinal bleeding, nocturnal symptoms that wake a patient from sleep, onset of symptoms after age 50 in the absence of prior history, or a significant family history of colorectal cancer or inflammatory bowel disease warrant more aggressive investigation. However, once appropriate evaluation has been performed and serious pathology ruled out, repeating extensive testing in the hope of finding a structural cause for chronic abdominal pain is rarely helpful and can exacerbate anxiety. Balancing appropriate vigilance for organic disease against the need to avoid over-investigation is a delicate but crucial part of the diagnostic process.
Another major challenge arises from the high prevalence of psychiatric comorbidity in these conditions and the historical tendency to categorize them as purely psychological. Depression, generalized anxiety, panic disorder, post-traumatic stress, and somatic symptom disorder frequently accompany FND, fibromyalgia, and IBS, yet they do not fully explain the symptom patterns. Clinicians must differentiate between symptoms that are best accounted for by primary psychiatric disorders (such as panic attacks presenting with chest pain and gastrointestinal upset) and those that fit more clearly with functional neurological or bodily distress syndromes. At the same time, dismissing psychiatric symptoms risks missing important contributors to symptom persistence and disability. A nuanced approach acknowledges that mood and anxiety disorders may both overlap with and amplify FND, fibromyalgia, or IBS, without implying that the latter are imaginary or “just stress-related.”
The concept of central sensitization offers a useful lens but also introduces diagnostic complexity. Because central sensitization can manifest as widespread pain, heightened sensory sensitivity, and overlapping symptoms across multiple organ systems, it may be present in fibromyalgia, IBS, FND, and other conditions such as chronic migraine, temporomandibular disorder, or chronic pelvic pain. Distinguishing whether a patient’s pain and fatigue stem predominantly from fibromyalgia, an inflammatory arthritis with secondary central sensitization, or a combination of both is not always straightforward. Moreover, some patients with central sensitization features may not meet full criteria for any single syndrome but instead occupy a gray zone of “undifferentiated” chronic bodily distress. Clinicians must therefore rely on pattern recognition, longitudinal observation, and the patient’s narrative rather than on a single biomarker or test result.
Misdiagnosis and delayed diagnosis are significant risks in both directions. On one hand, FND can be incorrectly labeled as epilepsy, stroke, or multiple sclerosis, leading to unnecessary medications, invasive procedures, or even surgery. People with fibromyalgia may be told for years that their symptoms are simply due to depression, aging, or degenerative disc disease, without receiving an integrated explanation that addresses their widespread pain and non-restorative sleep. Those with IBS can undergo repeated endoscopies, CT scans, and antibiotic courses for presumed infections without recognition of the functional nature of their bowel symptoms. On the other hand, over-attributing symptoms to FND, fibromyalgia, or IBS can mask evolving neurological, rheumatologic, or gastrointestinal pathology. Addressing this bidirectional risk requires humility, ongoing review, and readiness to revise diagnoses in light of new evidence.
Communication during the diagnostic process is particularly fraught. When test results are normal, patients may interpret statements such as “nothing is wrong” or “the tests are fine” as implying that their suffering is not real or not severe. Clinicians, under time pressure or uncertain about how to explain functional or overlapping syndromes, may resort to vague reassurances or suggest that “stress” is responsible, inadvertently reinforcing stigma. Effective communication instead requires framing FND, fibromyalgia, and IBS as genuine disorders of nervous system and bodily regulation, emphasizing that the absence of structural damage does not mean the absence of dysfunction. Presenting the diagnoses as positive findings—based on recognizable patterns and examination signs—can foster trust and reduce the sense of being dismissed.
Overlapping symptom clusters also create practical challenges in determining how many diagnostic labels to apply and how to prioritize them. One patient may clearly meet criteria for IBS, fibromyalgia, and FND, raising questions about whether these represent three distinct disorders or different expressions of a shared underlying vulnerability. In practice, the number of diagnoses attached to a patient’s record can influence eligibility for services, insurance coverage, and referral pathways. Too few labels may obscure the full scope of impairment and limit access to multidisciplinary care; too many may fragment care across specialties and reinforce a sense of being medically “complicated” or untreatable. Thoughtful diagnostic formulation often involves recognizing the specific syndromes present while also explicitly describing the overarching pattern of overlap and central sensitization.
Another differential consideration involves distinguishing functional symptoms from deliberate feigning or malingering, which is a concern for some clinicians but far less common than often assumed. People with FND, fibromyalgia, or IBS typically experience their symptoms as involuntary and distressing, and many go to great lengths to seek relief. Objective signs such as consistency of disability across contexts, collateral reports from family or caregivers, and the presence of typical positive examination findings support genuine functional or pain syndromes rather than intentional symptom production. Raising skepticism without clear evidence can significantly damage the therapeutic relationship, and the default stance should be to assume honesty while maintaining clinical curiosity and careful assessment.
The structure of healthcare systems can further complicate diagnosis and differential considerations. Patients often enter care through a single specialty—neurology for FND-like symptoms, rheumatology or pain clinics for fibromyalgia, and gastroenterology for IBS—and may receive evaluations narrowly focused on that organ system. When symptoms cross specialty boundaries, coordination may be limited, resulting in contradictory explanations or incomplete recognition of the overall pattern. For instance, a neurologist may appropriately diagnose FND but remain unaware of coexisting fibromyalgia and IBS that are driving much of the pain and fatigue; a gastroenterologist may manage IBS effectively while unaddressed functional motor symptoms cause major disability. Fragmentation of care increases the risk of partial or conflicting diagnoses and can delay the development of coherent management plans.
Cultural, gender, and socio-economic factors add additional complexity to diagnostic reasoning. Women, people from marginalized groups, and individuals with limited resources are more likely to have their symptoms minimized, psychologized, or misattributed to lifestyle factors. They may experience longer diagnostic delays, more negative healthcare encounters, and a higher burden of overlapping diagnoses. Language barriers and differing cultural explanations for bodily distress can complicate symptom description and clinician interpretation, leading to misalignment in understanding. Attention to these contextual influences is essential: differential diagnosis is not only a technical process of ruling conditions in or out but also a relational and social process shaped by power dynamics, bias, and access to care.
Ultimately, diagnostic challenges in the setting of overlapping FND, fibromyalgia, and IBS highlight the need for a more integrative clinical mindset. Rather than approaching each symptom cluster in isolation or defaulting to a binary choice between “organic” and “functional,” clinicians are tasked with discerning both the specific syndromes present and the shared mechanisms that connect them. This often involves accepting diagnostic uncertainty, using time as a diagnostic tool, and revisiting assumptions as new information emerges. By adopting a framework that legitimizes functional and central sensitization processes while remaining vigilant for coexisting structural disease, clinicians can navigate differential diagnosis more safely and constructively, reducing both under- and over-diagnosis and laying the groundwork for coordinated, patient-centered care.
Integrated management strategies across overlapping conditions
Management across these overlapping conditions works best when it is explicitly framed around the idea of shared mechanisms rather than isolated organ problems. Explaining to patients how FND, fibromyalgia, and IBS can all arise from changes in nervous system processing, autonomic regulation, and learned bodily responses can itself be therapeutic. A clear, coherent narrative that validates symptoms and highlights potential for change helps reduce fear, fosters engagement, and counters the demoralization that often follows years of fragmented care. This explanation should emphasize that symptoms are real but reversible to varying degrees, and that improving nervous system regulation often reduces pain and fatigue across multiple body systems at once.
An integrated care plan typically begins with collaborative goal setting that spans neurological, musculoskeletal, and gastrointestinal domains, rather than focusing on one diagnosis at a time. Specific, functional goals—such as walking to the mailbox without assistive devices, attending a social event without overwhelming IBS symptoms, or reducing the frequency of functional seizures—are more helpful than purely symptom-focused targets like “eliminate all pain.” Goals should be tiered into short-, medium-, and longer-term steps, allowing incremental successes to build confidence. Because central sensitization and autonomic dysregulation often make patients highly sensitive to changes, pacing and gradualism are essential to avoid overwhelming the system and precipitating flares.
Physiotherapy and graded movement therapies occupy a central role, especially in FND and fibromyalgia, but they must be adapted to the individual’s symptom pattern and beliefs. For FND, specialized physiotherapy focuses on retraining normal movement patterns using techniques such as distraction, automatic movements, and the use of visual feedback or mirrors to bypass maladaptive movement programs. For fibromyalgia, graded exercise—often starting with gentle stretching, walking, or aquatic therapy—aims to counteract deconditioning, improve sleep, and reduce pain sensitivity over time. When IBS is part of the picture, therapists may need to incorporate strategies for managing abdominal wall tension, diaphragmatic breathing, and postural support to lessen gastrointestinal discomfort. Across conditions, the emphasis is on consistency over intensity, with careful titration to avoid boom-and-bust cycles.
Occupational therapy complements physiotherapy by addressing the practical impact of symptom overlap on daily routines, work, and leisure. Occupational therapists can help patients assess energy expenditure, implement activity pacing, and restructure tasks to minimize symptom flare-ups while still encouraging gradual expansion of activity. For someone living with FND, fibromyalgia, and IBS, this might mean breaking household chores into shorter segments, planning rest periods proactively rather than reactively, and using ergonomic adaptations to reduce strain and abdominal pressure. Occupational therapy can also support planning for return to work or education, including graded hours, role adjustments, and environmental modifications to accommodate fatigue, sensory sensitivities, and unpredictable bowel symptoms.
Psychological interventions are most effective when presented as tools to modify brain–body interactions rather than as treatments for imagined illness. Cognitive-behavioral therapy (CBT) tailored to chronic pain and functional symptoms can help patients identify patterns of catastrophic thinking, all-or-nothing activity, and heightened symptom monitoring that perpetuate central sensitization. Techniques such as cognitive restructuring, behavioral activation, and graded exposure to feared activities are used to reduce avoidance and build resilience. In IBS, CBT may focus on reducing anticipatory anxiety about bowel symptoms and loosening rigid rules around food and toileting. For FND, CBT approaches often target fear of attacks or paralysis, beliefs about damage, and the way attention and expectations shape symptom onset and persistence.
Other psychological modalities can be equally important, especially when trauma, dissociation, or complex interpersonal dynamics are present. Trauma-focused therapies, such as EMDR or trauma-focused CBT, may be indicated when past abuse, accidents, or medical trauma have contributed to the development of hypervigilance and bodily threat responses. Psychodynamic or interpersonal therapies can help patients understand how emotional conflicts or relational patterns influence symptom flares and help them develop healthier coping strategies. Acceptance and commitment therapy (ACT) offers a framework for living a meaningful life alongside chronic symptoms by emphasizing values-based action and psychological flexibility rather than complete symptom elimination. Selection of modality should be individualized and communicated as part of a broader, biopsychosocial strategy to recalibrate the nervous system.
Education and self-management training form a core pillar of integrated care. Structured programs that teach patients about central sensitization, autonomic regulation, sleep hygiene, pacing, and stress management can significantly enhance outcomes across FND, fibromyalgia, and IBS. These programs may include group sessions, online modules, or written materials that normalize overlapping symptoms and provide concrete strategies. Skills training in relaxation (such as diaphragmatic breathing, progressive muscle relaxation, or guided imagery), mindfulness-based practices, and grounding techniques can reduce baseline arousal levels and improve interoceptive accuracy. Encouraging patients to track symptom patterns in relation to sleep, activity, diet, and stress can foster insight into triggers and reinforce a sense of agency.
Pharmacologic management in the context of overlap should prioritize multi-symptom benefit, minimal side effects, and avoidance of medications that reinforce disability. For fibromyalgia and centrally mediated pain, medications such as certain serotonin-norepinephrine reuptake inhibitors (SNRIs) or gabapentinoids can reduce pain intensity, improve sleep, and sometimes alleviate associated anxiety. Tricyclic antidepressants at low doses may be helpful for IBS-related pain and bowel irregularity, particularly in diarrhea-predominant subtypes, while also providing some benefit for sleep and mood. In FND, there is no specific pharmacologic cure for functional symptoms themselves, but treating comorbid depression, anxiety, or insomnia can indirectly reduce symptom frequency and severity. Caution is essential with opioids, benzodiazepines, and high-dose sedatives, as they can worsen central sensitization, impair cognition, promote dependence, and complicate functional recovery.
Dietary and gastrointestinal-focused interventions are particularly relevant when IBS coexists with fibromyalgia or FND, yet they should be integrated into a broader plan rather than pursued in isolation. Some patients benefit from limited trials of a low FODMAP diet, gluten reduction, or targeted elimination of clearly identified triggers such as caffeine or highly processed foods. However, overly restrictive diets can increase anxiety, social isolation, and nutritional risk, especially when pain and fatigue already limit activity. Working with a dietitian familiar with functional gastrointestinal disorders can help balance symptom control with variety and nutritional adequacy. Attention to meal timing, regular hydration, fiber intake (tailored to constipation or diarrhea), and mindful eating practices can improve bowel regularity and reduce postprandial discomfort.
Sleep optimization is a cross-cutting priority, given its powerful influence on pain thresholds, cognitive functioning, mood, and IBS symptom severity. Sleep-focused strategies include consistent bed and wake times, limiting naps, managing caffeine and screen exposure, and creating a quiet, dark sleep environment. For individuals with FND-related nocturnal events or fibromyalgia-associated restless legs and frequent awakenings, sleep medicine evaluation may be appropriate to assess for coexisting sleep apnea or periodic limb movement disorder. Non-pharmacologic approaches such as CBT for insomnia (CBT-I) often yield more durable benefits than sedative medications and can be integrated into existing psychological treatment plans.
Autonomic regulation techniques are especially important when patients experience orthostatic intolerance, palpitations, sweating, and temperature dysregulation that cut across diagnoses. Interventions may include graded upright training for orthostatic symptoms, hydration and salt optimization, compression garments, and gentle recumbent exercise progressing to upright activities. Biofeedback-based therapies, including heart rate variability (HRV) biofeedback, can teach patients to influence autonomic tone through controlled breathing and relaxation. Such approaches not only target cardiovagal regulation but can also decrease IBS-related urgency and cramping and reduce the bodily tension that fuels FND motor symptoms and fibromyalgia pain.
Mind–body and somatic therapies provide additional tools for integrating physical and psychological work. Approaches such as yoga, tai chi, Pilates, and Feldenkrais can improve body awareness, balance, and flexibility while promoting parasympathetic activation. These modalities may be especially useful for patients with distorted body schema, as in FND, or altered bodily perception, as in fibromyalgia, by offering a safe space to re-experience the body in motion. Somatic-focused psychotherapies and sensorimotor techniques can help patients notice and modulate bodily cues associated with emotional states, gradually decoupling automatic symptom responses from stress or relational triggers. These interventions should be tailored and introduced gradually, recognizing that some patients are initially fearful of movement or introspection due to prior experiences of symptom exacerbation.
Coordination among specialists is critical to prevent conflicting advice and redundant or harmful interventions. Ideally, a primary clinician—this may be a primary care provider, neurologist, physiatrist, or pain specialist—acts as the central point of contact, synthesizing input from neurology, rheumatology, gastroenterology, psychology, physiotherapy, and nutrition. Regular case conferences or shared care plans help ensure that all members of the team work from a common understanding of the patient’s overlapping conditions and treatment goals. Clear communication among providers about medication changes, physical activity recommendations, and psychological interventions prevents mixed messages, such as one clinician encouraging graded exercise while another recommends strict rest.
Patient empowerment and shared decision-making are essential to sustaining engagement over the long course typical of these conditions. Rather than prescribing a rigid, one-size-fits-all program, clinicians should collaborate with patients to prioritize interventions that align with their values, life context, and readiness for change. Some individuals may first want to stabilize sleep and IBS symptoms before addressing FND motor patterns; others may wish to focus on returning to work or parenting roles as primary goals. Using motivational interviewing techniques can help elicit ambivalence about change, explore barriers such as fear of symptom provocation, and enhance confidence in the ability to implement new strategies. Recognizing and celebrating small gains—such as a modest increase in walking distance or reduced absenteeism from social activities—reinforces progress and resilience.
Social and environmental supports are often underutilized components of integrated management. Families, partners, and close friends frequently struggle to understand the invisible yet disabling nature of overlapping FND, fibromyalgia, and IBS. Involving them in education sessions can reduce unhelpful responses such as overprotection or disbelief and encourage supportive behaviors that facilitate independence. Workplace accommodations, ranging from flexible scheduling and remote work options to ergonomic adjustments and access to private restrooms, can make the difference between ongoing employment and disability. Peer support groups, whether in-person or online, provide opportunities for validation, sharing of coping strategies, and reduction of isolation, though it is important to steer clear of communities that reinforce hopelessness or promote extreme, unproven treatments.
Addressing comorbid psychiatric and medical conditions is a necessary part of integrated management, not an optional add-on. Depression, anxiety disorders, PTSD, and substance use can all magnify symptom perception, reduce adherence to rehabilitation, and increase health-care utilization. Concurrent conditions such as migraines, pelvic pain, endometriosis, or autoimmune disease require coordinated care to avoid polypharmacy and conflicting treatment approaches. When other chronic illnesses are present, clinicians must help patients differentiate between symptom flares related to central sensitization and those signaling disease exacerbation, thereby reducing unnecessary emergency visits and investigations while maintaining safety.
Integrated management demands a long-term, iterative approach rather than a brief episode of care. Symptoms frequently fluctuate, and periods of progress may be followed by setbacks related to life stressors, infections, or changes in routine. Regular follow-up visits, even when symptoms are relatively stable, provide opportunities to reinforce strategies, adjust medications, revisit goals, and intervene early when warning signs of relapse emerge. Care plans should explicitly acknowledge the likelihood of ups and downs and frame them as expected parts of the recovery trajectory rather than as failures. This perspective supports persistence, reduces self-blame, and encourages a focus on overall functional improvement and quality of life, even when some degree of pain and fatigue remains.
Future directions for research and multidisciplinary care
Future research on these overlapping conditions needs to move beyond single-diagnosis studies and toward designs that intentionally recruit participants with combinations of FND, fibromyalgia, and IBS. Most existing trials exclude “complex” patients, which means the very individuals who experience the greatest burden of symptoms and disability are underrepresented in the evidence base. Large, longitudinal cohort studies that follow people with varying degrees of symptom overlap over many years could clarify how syndromes evolve, which factors predict transition from single-system symptoms to multi-system involvement, and which trajectories are associated with better or worse outcomes. Such work should include repeated assessments of pain and fatigue severity, autonomic function, mood, cognitive performance, and quality of life, rather than focusing narrowly on any one symptom domain.
Another priority is the development and validation of biomarkers that reflect shared mechanisms such as central sensitization, autonomic dysregulation, and altered interoception. While a single “blood test” for these disorders is unlikely, combining measures from multiple levels—functional and structural neuroimaging, quantitative sensory testing, heart rate variability, cortisol rhythms, inflammatory and neuroimmune markers, and gut microbiome profiles—may allow identification of reproducible subtypes that cut across traditional diagnostic lines. For example, one subgroup might show prominent autonomic instability and orthostatic intolerance, another might be characterized by high pain sensitivity and sleep disturbance, and yet another by strong associations with past trauma and dissociation. Identifying these mechanistic clusters would support more precise treatment matching and help explain why some people with FND, fibromyalgia, and IBS respond well to certain therapies while others do not.
Digital phenotyping and wearable technologies offer emerging tools to capture the everyday expression of overlapping symptoms with far greater resolution than occasional clinic visits can provide. Accelerometers, heart rate monitors, sleep trackers, and ecological momentary assessment apps can record fluctuations in activity, sleep, heart rate, bowel habits, and mood in real time, alongside self-reported pain, fatigue, and FND episodes. By linking these data to life events, stress levels, and treatment changes, researchers can begin to map individualized trigger patterns and recovery profiles. In clinical practice, these tools could support more responsive, data-informed care plans, with clinicians and patients jointly reviewing trends to fine-tune pacing, exercise, dietary changes, and psychological strategies.
Intervention research needs to systematically test integrated, multimodal care packages rather than isolated treatments. Many existing trials evaluate a single component—such as CBT, graded exercise, or a medication—often for one diagnosis at a time. Future randomized and pragmatic trials should assess combined programs that incorporate movement retraining for FND, chronic pain rehabilitation for fibromyalgia, IBS-focused dietary and behavioral strategies, and transdiagnostic psychological therapies targeting central sensitization and maladaptive predictive processing. Outcomes should be broad and include function, participation in work or school, social engagement, and patient-reported global improvement, not just symptom counts. Comparative effectiveness studies that test different combinations of therapies, delivered in varying intensities and formats (in-person, group, telehealth), would provide practical guidance for real-world service design.
Another important direction involves harnessing mechanistic insights to refine psychological and rehabilitative therapies. For example, predictive processing models suggest that symptom improvement may depend on carefully designed experiences that violate entrenched expectations of pain or paralysis in a safe context. Research can explore exposure-based movement therapies for FND that explicitly test feared actions, gut-directed neurocognitive retraining for IBS that alters anticipatory responses to meals and defecation, or sensory discrimination and body-mapping interventions for fibromyalgia that recalibrate distorted body representations. Clinical trials that include pre- and post-treatment imaging or neurophysiologic measures could show how these interventions modify brain circuits involved in attention, interoception, and threat detection, helping to bridge the gap between theory and practice.
Pharmacologic research must also adapt to the reality of overlapping syndromes. Instead of targeting one organ system, future trials could evaluate medications and biologics based on their impact on cross-cutting mechanisms such as descending pain modulation, sleep architecture, or microglial activation. Combination pharmacotherapy, when carefully designed and monitored, may prove beneficial for patients who have multiple conditions but share common pathophysiologic features. Adaptive trial designs that allow early identification of responders and non-responders, and that incorporate patient preferences and side-effect burden, would make pharmacologic research more relevant to heterogeneous clinical populations. Parallel work on deprescribing strategies is equally important, as many patients accumulate complex medication regimens over years; research should identify safe and effective ways to simplify treatments without destabilizing symptoms.
On the systems level, future directions in multidisciplinary care involve building and rigorously evaluating integrated clinics and care pathways that explicitly serve people with overlapping functional and pain syndromes. One model is a “centralized sensitization and functional disorders” service that includes neurology, gastroenterology, rheumatology or pain medicine, psychology, physiotherapy, occupational therapy, nursing, and dietetics, all working from common protocols and shared conceptual frameworks. Another is a virtual hub-and-spoke model in which specialized teams provide consultation, education, and care-planning support to primary care and community providers, expanding access beyond academic centers. Implementation research should examine not only symptom outcomes but also health-care utilization, costs, time to accurate diagnosis, patient satisfaction, and clinician burnout.
Care pathways should be designed to reduce duplication of investigations and prevent patients from cycling between specialties without resolution. Research can test stepped-care models that begin with low-intensity, widely accessible interventions—such as group education, digital CBT, and basic physiotherapy—and escalate to more specialized, resource-intensive treatments only when needed. Such models must account for individuals with severe disability or complex psychiatric comorbidities, who may require early referral to high-intensity multidisciplinary programs. Equity-focused evaluations should assess whether integrated pathways work as well for people from diverse racial, cultural, and socio-economic backgrounds, and whether modifications are needed to address specific barriers to engagement and continuity.
Education and training represent another major frontier. Studies are needed to determine which teaching approaches most effectively improve clinicians’ knowledge, attitudes, and skills in diagnosing and managing overlapping FND, fibromyalgia, and IBS. Simulation-based training, co-taught by clinicians and people with lived experience, may enhance empathy and communication skills while providing practical experience with positive diagnostic signs and collaborative explanation of functional mechanisms. Online curricula, case-based learning, and mentorship networks can support dissemination to community providers and trainees. Evaluations should measure not only knowledge gains but also changes in referral patterns, prescribing behavior, diagnostic delay, and patient-reported experiences of feeling believed and supported.
Patient and public involvement in research design is critical to ensure that future work addresses questions that matter most to those living with these conditions. Co-production models, in which patients serve as partners in setting priorities, selecting outcomes, and interpreting findings, can shift the research agenda toward issues such as stigma reduction, employment support, parenting with chronic illness, and navigating benefits systems. Trials and cohort studies should routinely incorporate qualitative components to capture nuanced experiences of living with overlapping diagnoses, responses to treatment, and reasons for disengagement from care. These insights can guide refinement of interventions and improve their acceptability and cultural fit across diverse populations.
Technology-enabled self-management supports are likely to become central components of multidisciplinary care. Digital platforms that integrate educational modules, symptom tracking, goal setting, and direct messaging with care teams can provide ongoing scaffolding between clinic visits. Research should evaluate which features—such as tailored feedback, peer support forums, gamified progress tracking, or automated alerts to clinicians about concerning trends—actually improve adherence, reduce symptom impact, and enhance quality of life. Particular attention is needed to digital equity, ensuring that these tools are accessible to people with limited literacy, variable internet access, cognitive difficulties, or sensory sensitivities related to pain and fatigue.
Across all of these domains, a key future direction is the explicit recognition and study of heterogeneity within and between FND, fibromyalgia, and IBS. Rather than assuming a single pathway, researchers and clinicians will need to embrace the reality that multiple mechanisms can lead to similar clinical pictures, and that different combinations of interventions will be needed for different people. Sophisticated analytic methods, such as machine learning applied to multidimensional datasets, may help identify meaningful subgroups and predict which patients are most likely to benefit from particular treatment packages. Over time, this precision-medicine approach—grounded in mechanisms but attentive to context—has the potential to transform how overlapping functional and pain syndromes are understood, studied, and managed within multidisciplinary care systems.
